Class Action Suit Filed Over Plavix Risks And Benefits
This article was originally published in The Pink Sheet Daily
Executive Summary
Lawsuit alleges that Bristol and Sanofi "duped" payers into paying for prescriptions of the anti-coagulant.
You may also be interested in...
Plavix Sales Plummet With Generic Entry
Bristol estimates that “at risk” launch of generic clopidogrel impacted U.S. pharma sales by $525 mil. to $600 mil.
CHARISMA Suggests Benefit Of Combo Antiplatelet Therapy In Patients With Established CV Disease
Overall study group, however, did not show reduction in risk in combined rate of death, heart attack or stroke from combination therapy of Plavix and low-dose aspirin.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.